This work is licensed under a Creative Commons Attribution 4.0 International License.
Tfr-lytic
General Information
DRACP ID DRACP01393
Peptide Name Tfr-lytic
Sequence THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK
Sequence Length 32
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| T-47D | Invasive breast carcinoma of no special type | Carcinoma | IC50=4.8μM | WST-8 assay | 72h | Patent |
| MDA-MB-231 | Breast adenocarcinoma | Carcinoma | IC50=6.7μM | WST-8 assay | 72h | Patent |
| SK-BR-3 | Breast adenocarcinoma | Carcinoma | IC50=5.3μM | WST-8 assay | 72h | Patent |
| LNCaP | Prostate carcinoma | Carcinoma | IC50=6.2μM | WST-8 assay | 72h | Patent |
| U251 | Astrocytoma | Carcinoma | IC50=6.8μM | WST-8 assay | 72h | Patent |
| SN19 | Glioblastoma | Blastoma | IC50=8.2μM | WST-8 assay | 72h | Patent |
| COLO 587 | Colon adenocarcinoma | Carcinoma | IC50=6.9μM | WST-8 assay | 72h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity MRC-5: IC50>20μM; HC cell: IC50>20μM; PE cell: IC50>20μM
Target Transferrin Receptor (TfR)
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification l=D-Leucine; k=D-Lysine
Chiral Mix
Physicochemical Information
Formula C149H236N40O25S
Absent amino acids ACDEFINQY
Common amino acids KL
Mass 357294
Pl 12.1
Basic residues 8
Acidic residues 0
Hydrophobic residues 9
Net charge 8
Boman Index -1546
Hydrophobicity -40.94
Aliphatic Index 82.19
Half Life
/
Extinction Coefficient cystines 11000
Absorbance 280nm 354.84
Polar residues 5
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2011/0319336 A1
Patent Title Selective anticancer chimeric peptide.
Other Iinformation Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013
Other Published ID CN102238965A EP2370107A2 WO2010064207A2 WO2010064207A3
This work is licensed under a Creative Commons Attribution 4.0 International License.